Last updated on August 2020

Phase III Radium 223 mCRPC-PEACE III

Brief description of study

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Clinical Study Identifier: NCT02194842

Find a site near you

Start Over

AZ Turnhout

Turnhout, Belgium
  Connect »


Copenhagen, Denmark
  Connect »

Gustave Roussy

Villejuif, France
  Connect »


Bern, Switzerland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.